DGAP-News: Genmab Announces Financial Results for the First Quarter of 2013
(firmenpresse) - Genmab A/S
07.05.2013 17:02
---------------------------------------------------------------------------
May 7, 2013; Copenhagen, Denmark;
Interim Report First Quarter 2013
-- Arzerra(r) received approval in Japan
-- Arzerra net sales increased 65% over Q1 2012
-- Manufacturing facility sold to Baxter
-- Improved operating result by DKK 73 million over Q1 2012
'We expect 2013 to be another exciting and productive year at Genmab and are
working hard to fulfill the objectives we set for this year. We were pleased to
gain approval for Arzerra in Japan, the first Asian territory to give marketing
authorization to the product, as well as to see growing sales during Q1. We
recently reported impressive top line results from a Phase II study using
ofatumumab together with bendamustine to treat CLL patients and look forward to
reporting important Phase III data from our frontline CLL study with ofatumumab
in the coming time,' said Jan van de Winkel, Ph.D., Chief Executive Officer of
Genmab.
Financial Performance First Quarter
-- Genmab's revenue was DKK 160 million for the first quarter of 2013 compared
to DKK 94 million for the corresponding period in 2012. The increase of DKK
66 million or 70% was mainly driven by higher Arzerra royalties, revenue
related to our daratumumab collaboration with Janssen Biotech (Janssen) and
the achievement of a milestone under our collaboration with GlaxoSmithKline
(GSK).
-- Operating expenses decreased 5% from DKK 138 million in the first quarter
of 2012 to DKK 131 million in the first quarter of 2013.
-- Operating income was DKK 29 million in the first quarter of 2013 compared
to an operating loss of DKK 44 million in the corresponding period for
2012, an improvement of DKK 73 million. The improved operating result was
driven by increased revenue and continued strong focus on cost control.
-- The net result for discontinued operation amounted to a net income of DKK
42 million in the first quarter of 2013. The net income in 2013 related to
the final few months of running costs of the Minnesota manufacturing
facility of DKK 10 million prior to its divestiture and a gain on the sale
of DKK 52 million. The facility maintenance cost amounted to DKK 10 million
in the first quarter of 2012.
-- On March 31, 2013, Genmab had a cash position of DKK 1,554 million. This
represented a net increase of DKK 38 million from the beginning of 2013,
which was primarily related to proceeds received from the sale of the
manufacturing facility. The cash burn for the first quarter of 2012 was DKK
74 million.
Business Progress First Quarter to Present
-- February: The Minnesota manufacturing facility was sold to Baxter
Healthcare (Baxter) Corporation for USD 10 million.
-- March: Arzerra received approval in Japan for use in patients with
relapsed/refractory CD20-positive chronic lymphocytic leukemia (CLL). The
approval triggered a milestone payment of DKK 20 million from GSK to
Genmab.
-- April: The US Food and Drug Administration (FDA) granted Fast Track
designation for daratumumab. This designation covers patients with multiple
myeloma who have received at least three prior lines of therapy including a
proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or are
double refractory to a PI and anIMiD.
-- April:
GSK reported net sales for Arzerra for the first quarter of 2013 of GBP
20.5 million, an increase of 65% over Q1 2012, resulting in royalty income
of DKK 36 million to Genmab. A large portion of the rest of the world sales
in the first quarter of 2013 were related to the supply of ofatumumab for
clinical trials run by other companies, and as such does not reflect
ongoing commercial demand.
-- April: The U.S. Court of Appeals for the Federal Circuit upheld the U.S.
District Court's judgment in favor of GSK in a patent infringement case
involving Arzerra brought against GSK by Genentech and Biogen Idec.
-- May: Reported impressive top line data from a Phase II study of ofatumumab
in combination with bendamustine in patients with untreated or relapsed
CLL. The overall response rate (ORR) in the study was 95% in previously
untreated patients and 74% in patients with relapsed CLL.
-- May: The US FDA granted Breakthrough Therapy Designation for daratumumab
for the treatment of patients with multiple myeloma who have received at
least three prior lines of therapy including a PI and an IMiD or who are
refractory to a PI and an IMiD.
Outlook
Genmab is maintaining its 2013 financial guidance as announced on March 7, 2013.
Conference Call
Genmab will hold a conference call in English to discuss the results for the
first quarter of 2013 today, Tuesday, May 7, at 6.00 pm CEST, 5.00 pm BST or
noon EDT. The dial in numbers are:
+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555 131 (international participants) and ask for the Genmab conference
call
A live and archived webcast of the call and relevant slides will be available
at www.genmab.com.
ABOUT GENMAB A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations&Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen(at)genmab.com
This interim report contains forward looking statements. The words 'believe',
'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the section
'Risk Management' in Genmab's annual report, which is available on
www.genmab.com and the 'Significant Risks and Uncertainties' section in this
interim report. Genmab does not undertake any obligation to update or revise
forward looking statements in this interim report nor to confirm such
statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); the DuoBody logo(r); HuMax(r); HuMax-CD20(r);
DuoBody(r); HexaBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r) is
a trademark of GlaxoSmithKline.
Company Announcement no. 20
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=431831
News Source: NASDAQ OMX
07.05.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Dänemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2013 - 17:02 Uhr
Sprache: Deutsch
News-ID 257130
Anzahl Zeichen: 4906
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Genmab Announces Financial Results for the First Quarter of 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Genmab A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
